51. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors
- Author
-
Clemens, Eva, Andrica CH De Vries, Zehnhoff-Dinnesen, Antoinette Am, Tissing, Wim JE, Loonen, Jacqueline J, Pluijm, Saskia FM, Broeder, Eline Van Dulmen-Den, Bresters, Dorine, Versluys, Birgitta, Kremer, Leontien CM, Pal, Helena J Van Der, Neggers, Sebastian JCCM, Grotel, Martine Van, and Heuvel-Eibrink, Marry M Van Den
- Subjects
otorhinolaryngologic diseases ,3. Good health - Abstract
Cisplatin and carboplatin are effective antineoplastic agents. They are also considered to be potentially highly ototoxic. To date, no long-term follow-up data from well-documented cohorts with substantial numbers of childhood cancer survivors (CCS) with platinum-related hearing loss are available. Therefore, in this study, we studied the reversibility of ototoxicity from discontinuation of treatment onwards in a national cohort of platinum-treated survivors with hearing loss at the end of cancer treatment. Of the 168 CCS with follow-up audiograms, we longitudinally evaluated the course of hearing function in 61 CCS who showed hearing impairment at discontinuation of treatment according to the Münster criteria (>20 dB at ≥4–8 kHz). Survivors were treated with platinum (median total cumulative dose cisplatin: 480 mg/m2 and median total cumulative dose carboplatin: 2520 mg/m2). Median follow-up time was 5.5 years (range: 1.0–28.8 years). The results showed that none of these survivors revealed improvement of hearing function even till 28.8 years after discontinuation of treatment (grade